NASDAQ · NRXP
Healthcare · Biotechnology
$2.87
Down-$0.13 (-4.17%)
Updated Sep 29, 2026, 8:52 AM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · NRXP
1M range · 20 trading sessions · Daily adjusted prices
Prices through Sep 28, 2026
NRXP closed at $2.87 after 20 trading sessions, down 17.53% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 28, 2026 | $2.95 | $3.01 | $2.87 | $2.87 | 735.91K |
| Sep 25, 2026 | $3.07 | $3.09 | $2.92 | $2.995 | 793.38K |
| Sep 24, 2026 | $3.15 | $3.15 | $3.025 | $3.03 | 681.05K |
| Sep 23, 2026 | $3.29 | $3.35 | $3.12 | $3.16 | 552.5K |
| Sep 22, 2026 | $3.30 | $3.33 | $3.21 | $3.32 | 495.04K |
| Sep 21, 2026 | $3.37 | $3.39 | $3.29 | $3.29 | 380.01K |
| Sep 18, 2026 | $3.38 | $3.42 | $3.31 | $3.32 | 947.27K |
| Sep 17, 2026 | $3.38 | $3.52 | $3.36 | $3.39 | 789.02K |
| Sep 16, 2026 | $3.39 | $3.45 | $3.32 | $3.35 | 716.04K |
| Sep 15, 2026 | $3.46 | $3.47 | $3.16 | $3.40 | 1.26M |
| Sep 14, 2026 | $3.37 | $3.605 | $3.35 | $3.49 | 1.21M |
| Sep 11, 2026 | $3.44 | $3.44 | $3.37 | $3.40 | 356.23K |
| Sep 10, 2026 | $3.36 | $3.45 | $3.32 | $3.40 | 480.12K |
| Sep 9, 2026 | $3.48 | $3.52 | $3.34 | $3.37 | 520.71K |
| Sep 8, 2026 | $3.50 | $3.54 | $3.42 | $3.47 | 705.97K |
| Sep 4, 2026 | $3.43 | $3.50 | $3.39 | $3.49 | 487.72K |
| Sep 3, 2026 | $3.48 | $3.50 | $3.425 | $3.43 | 237.36K |
| Sep 2, 2026 | $3.46 | $3.50 | $3.38 | $3.46 | 418.34K |
| Sep 1, 2026 | $3.45 | $3.51 | $3.42 | $3.44 | 392.76K |
| Aug 31, 2026 | $3.52 | $3.545 | $3.43 | $3.48 | 427.01K |
The latest Smart Investors Daily articles mentioning NRXP.
NRXP research
Company profile and research snapshot.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 14, 2026 | BTIG | Buy | — |
| Aug 25, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 18, 2026 | BTIG | Buy | — |
| Aug 7, 2026 | BTIG | Buy | — |
| May 5, 2026 | D. Boral Capital | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 24, 2026
Ono Pharmaceutical Co. (OPHLF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Yahoo · Sep 15, 2026
Abbreviated New Drug Application (ANDA) Amendment related to the drug vial for preservative-free ketamine has been reclassified from a Major Amendment to a Minor Amendment.FDA has revised the Generic Drugs User Fee Act (GDUFA) Goal Date to November 10, 2026. WILMINGTON, Del., Sept. 15, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it has received a written communi
Benzinga · Sep 15, 2026
Abbreviated New Drug Application (ANDA) Amendment related to the drug vial for preservative-free ketamine has been reclassified from a Major Amendment to a Minor Amendment.FDA has revised the Generic Drugs User Fee Act
Benzinga · Sep 14, 2026
BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $10 price target.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NRXP.
